January 28th 2022
By Laura Joszt
In a deal to sell the 50% ownership stake, Biogen would receive up to $2.3 billion.
January 15th 2022
By Tony Hagen
The International Generic and Biosimilar Medicines Association has appointed a veteran member, Vivian Frittelli, MBA, ACIS, to take over as chair.
January 13th 2022
Ford Motor saved $5 million by switching patients to 5 biosimilars, and other manufacturers and employers in Michigan have achieved good results with switching programs, the Economic Alliance of Michigan reports.
January 11th 2022
By Meir Rinde, MS
In a recent paper, Sarfaraz K. Niazi, PhD summarizes some of his central ideas on the relevance of FDA biosimilar testing standards.
January 10th 2022
Simlandi (AVT02) is the second high-concentration, citrate-free adalimumab (Humira) biosimilar to be approved in the Canada market.
January 8th 2022
In India, an emphasis on outdated biosimilar testing has restricted market entry of these products and discouraged manufacturers, patient advocates contend.
January 5th 2022
The companies hope to gain FDA approval for a high-concentration, citrate-free version of Hadlima, an adalimumab biosimilar that was approved in a lower concentration in July 2019.
January 4th 2022
Savings from adalimumab biosimilars, which won't enter the US market until 2023, account for a significant share of the total, investigators said.
January 1st 2022
Biosimilars have produced more than $20 billion of savings in Europe, but more use of these agents is needed.
December 21st 2021
The year 2021 brought several firsts in biosimilars and set the stage for expansion across therapeutic areas including diabetes and ophthalmology.
